相关实验视频

Updated: Jul 3, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K

针对EGFR突变晚期肺腺癌的向治疗后,复杂的小细胞转化与缩性肺骨关节病变:一个病例报告

Sijia Zhang1, Leichong Chen1, Kuikui Zhu1

  • 1Cancer Center, Union Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Indian journal of pathology & microbiology
|February 15, 2024
PubMed
概括

对EGFR突变肺癌的精密疗法面临阻力. 早期诊断高缩小性肺性骨关节病 (HPOA) 可能预测目标耐药性和肺腺癌的病理转化.

关键词:
案例报告案例报告在EGFR突变的过程中,缩性肺性骨关节病 (HPOA) 是一种小细胞转化转化小细胞转化针对性治疗的耐药性是针对性的.

更多相关视频

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.0K

相关概念视频

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K